Title Kardiotoksičnost kao posljedica liječenja maligne bolesti
Title (english) Cardiotoxicity as a consequence of malignant disease treatment
Author Jakov Božiković
Mentor Teodora Zaninović Jurjević (mentor)
Mentor Neven Franjić (komentor)
Committee member Ivan Bubić (predsjednik povjerenstva)
Committee member Zlatko Čubranić (član povjerenstva)
Committee member Vjekoslav Tomulić (član povjerenstva)
Granter University of Rijeka Faculty of Medicine (Department of Internal Medicine) Rijeka
Defense date and country 2022-07-15, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Internal Medicine
Abstract Vodeći uzroci mortaliteta i morbiditeta u razvijenim zemljama svijeta su maligne i kardiovaskularne bolesti. Progresivnim starenjem stanovništva i izlaganjem rizičnim čimbenicima dolazi do porasta prevalencije ovih bolesti te je velika vjerojatnost da onkološki bolesnici istodobno imaju i kardiovaskularnu bolest.
Iako napredak u liječenju malignih bolesti dovodi do sve dužeg preživljenja, zbog štetnih učinaka onkološke terapije raste rizik za pogoršanje postojećih kardiovaskularnih bolesti ili razvoj novih komplikacija koje se mogu manifestirati simptomatskim zatajivanjem srca, poremećajima srčanog ritma i provođenja, ishemijskom bolesti srca, tromboembolijskm incidentima te upalnim i valvularnim bolestima srca. Ipak, jedna od najznačajnijih posljedica je oštećenje miokarda, odnosno zatajivanje srca što se i najčešće podrazumijeva pod pojmom kardiotoksičnosti. Navedene se komplikacije mogu razviti nedugo nakon početka primjene terapije, ali i nekoliko godina od završetka onkološkog liječenja. Težina kliničke slike ovisi prije svega o vrsti primijenjene terapije, ali i o apliciranim dozama, duljini trajanja terapije i osjetljivosti bolesnika. Osim otprije poznatih kardiotoksičnih učinaka kemoterapije, kardiološke nuspojave ne izostaju niti kod primjene novijih bioloških lijekova i imunoterapije. U ovom radu su opisani najčešće korišteni lijekovi kao predstavnici pojedinih terapijskih skupina, mehanizmi kojima ostvaruju kardiotoksične učinke i incidencija komplikacija povezanih s njihovom primjenom.
Pojava kardiovaskularne bolesti tijekom ili nakon onkološkog liječenje znatno utječe na ishod osnovne bolesti, odnosno na kvalitetu života nakon prestanka onkološkog liječenja. S ciljem osiguranja što bolje skrbi za pacijente na onkološkoj terapiji, neophodno je redovito kardiološko praćenje kako za vrijeme, tako i nakon završetka liječenja.
Abstract (english) The leading causes of mortality and morbidity in the developed countries of the world are malignant and cardiovascular diseases. Progressive aging of the population and exposure to risk factors increase the prevalence of these diseases and it is very likely that cancer patients also have cardiovascular disease at the same time.
Although advances in the treatment of malignancies lead to longer survival, the adverse effects of oncology therapy increase the risk of exacerbation of existing cardiovascular disease or the development of new complications that may manifest as symptomatic heart failure, cardiac arrhythmias and conduction disorders, ischemic heart disease, thromboembolic incidents and inflammatory and valvular heart diseases. However, one of the most significant consequences is myocardial damage, ie heart failure, which is most often understood as cardiotoxicity. These complications can develop shortly after the start of therapy, but also several years after the end of oncological treatment. The severity of the clinical picture depends primarily on the type of therapy used, but also on the applied doses, the duration of therapy and the sensitivity of the patient. In addition to the previously known cardiotoxic effects of chemotherapy, cardiac side effects are not absent neither with the use of newer biological drugs and immunotherapy. This paper describes the most commonly used drugs as representatives of individual therapeutic groups, the mechanisms by which they achieve cardiotoxic effects and the incidence of complications associated with their use.
The occurrence of cardiovascular disease during or after oncological treatment significantly affects the outcome of the underlying disease, ie the quality of life after cessation of oncological treatment. In order to ensure the best possible care for patients on oncology therapy, regular cardiac monitoring is necessary both during and after the end of treatment.
Keywords
kardiotoksičnost
liječenje
maligna bolest
Keywords (english)
cardiotoxicity
malignancy
treatment
Language croatian
URN:NBN urn:nbn:hr:184:650264
Study programme Title: Medicine Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resource Text
File origin Born digital
Access conditions Open access
Terms of use
Created on 2022-07-11 09:56:32